132 related articles for article (PubMed ID: 28069554)
1. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
3. Liposomal co-encapsulation of a novel gemini lipopeptide and a CpG-ODN induces a strong Th1 response with the co-activation of a Th2/Th17 profile and high antibody levels.
Reidel IG; Curti CC; Dorémus L; Béré E; Delwail A; Russi RC; Lecron JC; Morel F; García MI; Müller DM; Jégou JF; Veaute CM
Vaccine; 2024 Mar; 42(8):1953-1965. PubMed ID: 38378388
[TBL] [Abstract][Full Text] [Related]
4. CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged.
Sharma S; Dominguez AL; Hoelzinger DB; Lustgarten J
Cancer Immunol Immunother; 2008 Apr; 57(4):549-61. PubMed ID: 17828396
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity.
Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG
Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279
[TBL] [Abstract][Full Text] [Related]
6. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
[TBL] [Abstract][Full Text] [Related]
7. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.
Johnston D; Zaidi B; Bystryn JC
Cancer Immunol Immunother; 2007 Aug; 56(8):1133-41. PubMed ID: 17139492
[TBL] [Abstract][Full Text] [Related]
8. Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system.
Cheng L; Zhang Z; Li G; Li F; Wang L; Zhang L; Zurawski SM; Zurawski G; Levy Y; Su L
Vaccine; 2017 Oct; 35(45):6143-6153. PubMed ID: 28958808
[TBL] [Abstract][Full Text] [Related]
9. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice.
Hansen J; Lindenstrøm T; Lindberg-Levin J; Aagaard C; Andersen P; Agger EM
Cancer Immunol Immunother; 2012 Jun; 61(6):893-903. PubMed ID: 22095092
[TBL] [Abstract][Full Text] [Related]
10. Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.
Abhyankar MM; Noor Z; Tomai MA; Elvecrog J; Fox CB; Petri WA
Vaccine; 2017 Feb; 35(6):916-922. PubMed ID: 28089548
[TBL] [Abstract][Full Text] [Related]
11. Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.
Kitahata Y; Kanuma T; Hayashi M; Kobayashi N; Ozasa K; Kusakabe T; Temizoz B; Kuroda E; Yamaue H; Coban C; Yamamoto T; Kobiyama K; Aoshi T; Ishii KJ
Oncotarget; 2016 Aug; 7(31):48860-48869. PubMed ID: 27384490
[TBL] [Abstract][Full Text] [Related]
12. CpG DNA as a vaccine adjuvant.
Bode C; Zhao G; Steinhagen F; Kinjo T; Klinman DM
Expert Rev Vaccines; 2011 Apr; 10(4):499-511. PubMed ID: 21506647
[TBL] [Abstract][Full Text] [Related]
13. Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection.
Hickey AJ; Lin JS; Kummer LW; Szaba FM; Duso DK; Tighe M; Parent MA; Smiley ST
Infect Immun; 2013 Jun; 81(6):2123-32. PubMed ID: 23545300
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice.
Johnston D; Reynolds SR; Bystryn JC
Cancer Immunol Immunother; 2006 Apr; 55(4):412-9. PubMed ID: 16151809
[TBL] [Abstract][Full Text] [Related]
15. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
Jeon D; Hill E; Moseman JE; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
[TBL] [Abstract][Full Text] [Related]
16. Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses.
Roux S; Bernat C; Al-Sakere B; Ghiringhelli F; Opolon P; Carpentier AF; Zitvogel L; Mir LM; Robert C
Cancer Immunol Immunother; 2008 Sep; 57(9):1291-300. PubMed ID: 18259749
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor.
Yao Y; Li J; Qu K; Wang Y; Wang Z; Lu W; Yu Y; Wang L
Cancer Immunol Immunother; 2023 May; 72(5):1103-1120. PubMed ID: 36326892
[TBL] [Abstract][Full Text] [Related]
18. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection.
Klinman DM; Conover J; Coban C
Infect Immun; 1999 Nov; 67(11):5658-63. PubMed ID: 10531213
[TBL] [Abstract][Full Text] [Related]
19. Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands.
Klein JC; Wild CA; Lang S; Brandau S
Cancer Immunol Immunother; 2016 Jun; 65(6):689-700. PubMed ID: 27034235
[TBL] [Abstract][Full Text] [Related]
20. Accelerated wound healing mediated by activation of Toll-like receptor 9.
Sato T; Yamamoto M; Shimosato T; Klinman DM
Wound Repair Regen; 2010; 18(6):586-93. PubMed ID: 20946144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
